Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ICPT

Intercept Pharmaceuticals (ICPT) Stock Price, News & Analysis

Intercept Pharmaceuticals logo

About Intercept Pharmaceuticals Stock (NASDAQ:ICPT)

Advanced Chart

Key Stats

Today's Range
$19.00
$19.00
50-Day Range
$18.20
$19.00
52-Week Range
$8.82
$21.86
Volume
N/A
Average Volume
1.36 million shs
Market Capitalization
$794.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..

Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ICPT Stock News Headlines

New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
See More Headlines

ICPT Stock Analysis - Frequently Asked Questions

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) released its earnings results on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.42. The business's quarterly revenue was up 16.6% compared to the same quarter last year.
Read the conference call transcript
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Intercept Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Sarepta Therapeutics (SRPT), Netflix (NFLX), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

Last Earnings
8/02/2023
Today
4/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ICPT
Employees
341
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$221.82 million
Pretax Margin
-18.09%

Debt

Sales & Book Value

Annual Sales
$285.71 million
Price / Cash Flow
N/A
Book Value
$1.72 per share
Price / Book
11.05

Miscellaneous

Free Float
39,192,000
Market Cap
$794.77 million
Optionable
Optionable
Beta
0.88

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:ICPT) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners